TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com
To the OMX Nordic Exchange Copenhagen
Announcement No. 26-07 / Copenhagen 11 July 2007
Major Shareholder Announcement
On behalf of Massachusetts Financial Services Investment Management, TopoTarget
A/S announces the following:
Pursuant to the Danish Securities Trading Act and Executive Order on
Assessment, Notification and Disclosure of Major Holdings in Companies with
Shares Listed on a Stock Exchange or Traded in an Authorized Market Place
(Executive Order No. 274 of 21 March 2007), this serves as notice of
substantial shareholder disclosure for Massachusetts Financial Services Company
and its investment advisory subsidiaries (“MFS”), which serve as investment
manager for its various mutual funds, institutional account and other advisory
clients.
According to announcement No. 25-07 / sent to the OMX Nordic Exchange
Copenhagen, 29 June 2007. TopoTarget has increased the total shares rights to
61,304,510; causing MFS and its various subsidiaries to fall below 5% ownership
of TopoTarget A/S on 2 July 2007. As of end day, 2 July 2007, MFS on behalf of
its various clients*, held 3,009,074 shares, equivalent to 4.91% of the total
issued share capital of TopoTarget A/S (based on 61,304,510 total shares
outstanding). Please note that of 4.91% of total shares held by MFS, 2.45%
represents shares where MFS has discretionary voting power. Various subsidiary
investment advisers of MFS manage the shareholdings, which are set forth below:
MFS International Ltd.: 127,800 Shares 0.21%
MFS International (U.K.) Ltd.: 1,015,200 Shares 1.66%
MFS Investment Management (Lux) S.A.: 1,032,500 Shares 1.68%
MFS Institutional Advisors, Inc.: 853,574 Shares 1.36%
*MFS Clients, including the mutual funds and other institutional accounts, are
the actual shareholders of the shares discussed herein, where MFS holds
investment discretion and, in most cases voting discretion over such shares.
TopoTarget A/S
For further information, please contact:
Dr. Peter Buhl Jensen Telephone +45 39 17 83 41
Chief Executive Officer Mobile +45 21 60 89 22
Background information
About TopoTarget
TopoTarget (OMX - The Nordic Exchange: TOPO) is a biopharmaceutical company,
headquartered in Denmark and with subsidiaries in the UK, Germany, Switzerland
and the USA, dedicated to finding ''Answers for Cancer'' and developing
improved cancer therapies. TopoTarget is founded and run by clinical cancer
specialists and combines years of hands-on clinical experience with in-depth
understanding of the molecular mechanisms of cancer. Focus lies on highly
predictive cancer models and key cancer targets (including HDAC, NAD+,
FasLigand, mTOR, and topoisomerase II inhibitors) and a strong development
foundation has been built. TopoTarget has a broad portfolio of small molecule
pre-clinical drug candidates and eight drugs are in clinical development,
including both novel anti-cancer therapeutics and new cancer indications for
existing drugs. Savene™ is TopoTarget's first product on the market. The
product is expected to be approved and launched in the US in the second half of
2007. In addition to organic growth, TopoTarget consistently looks for
opportunities to strengthen and expand its activities through acquisitions and
in-licensing. For more information, please refer to www.topotarget.com.
TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. TopoTarget cautions investors
that there can be no assurance that actual results or business conditions will
not differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: the risk that any one or more of the drug development programs of
TopoTarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks; uncertainty of additional funding; TopoTarget's history of
incurring losses and the uncertainty of achieving profitability; TopoTarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against TopoTarget's products, processes and
technologies; the ability to protect TopoTarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability expo-sure; We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law.
